검색어 : 통합검색[Vanderbilt Tom]
총 377건 중 377건 출력
, 36/38 페이지
-
351
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
- Plimack, Elizabeth R.; Rini, Brian I.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Fré dé ric; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L. Rhoda; Atkins, Michael B.; Powles, Thomas; Fox Chase Cancer Center, Philadelphia, PA; ; Vanderbilt-Ingram Cancer Center, Nashville, TN; ; Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro, Ukraine; ; Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation; ; The Christie NHS Foundation Trust, Manchester, United Kingdom; ; Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation; ; CHU of Quebec and Laval University, Quebec City, ON, Canada; ; Centre Hospitalier de l'Université de Montré al, Montré al, QC, Canada; ; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; ; Sumy State University, Sumy Regional Oncology Center, Sumy, Ukraine; ; Hospital de Clí nicas de Porto Alegre, Porto Alegre, Brazil; ; Centre Antoine Lacassagne, Université Cô te d’Azur, Nice, France; ; Adelaide and Meath Hospital and University College Dublin, Dublin, Ireland; ; Eberhard-Karls University Tü bingen, Tü bingen, G; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.38, 2020, pp.5001-5001)
-
352
- Spinal cord grey matter segmentation challenge
- Prados, Ferran; Ashburner, John; Blaiotta, Claudia; Brosch, Tom; Carballido-Gamio, Julio; Cardoso, Manuel Jorge; Conrad, Benjamin N.; Datta, Esha; Dá vid, Gergely; Leener, Benjamin De; Dupont, Sara M.; Freund, Patrick; Wheeler-Kingshott, Claudia A.M. Gandini; Grussu, Francesco; Henry, Roland; Landman, Bennett A.; Ljungberg, Emil; Lyttle, Bailey; Ourselin, Sebastien; Papinutto, Nico; Saporito, Salvatore; Schlaeger, Regina; Smith, Seth A.; Summers, Paul; Tam, Roger; Yiannakas, Marios C.; Zhu, Alyssa; Cohen-Adad, Julien; Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, Malet Place Engineering Building, London WC1E 6BT, UK; Wellcome Trust Centre for Neuroimaging, University College London, Queen Square, London WC1N 3BG, UK; Wellcome Trust Centre for Neuroimaging, University College London, Queen Square, London WC1N 3BG, UK; Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, Canada V6T 1Z4; Department of Neurology, University of California San Francisco, San Francisco, CA, USA; Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, Malet Place Engineering Building, London WC1E 6BT, UK; Department of Electrical Engineering, Computer Science, Biomedical Engineering, Radiology and Radiological Sciences, Institute of Image Science at Vanderbilt University, Nashville; (NeuroImage, v.152, 2017, pp.312-329)
-
353
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
- Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor O.; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Wu, Sterling; Burgents, Joseph; Molife, L. Rhoda; Powles, Thomas; Vanderbilt-Ingram Cancer Center, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; Dnipro State Medical University, Dnipro, Ukraine; Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation; Christie Hospital, Manchester, United Kingdom; Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation; CHU of Quebec and Laval University, Quebec, QC, Canada; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russian Federation; Centre Hospitalier de l’Université de Montré al, Montreal, QC, Canada; Palacky University Medical School, Olomouc, Czech Republic; Sumy State University, Sumy, Ukraine; Hospital de Clí nicas de Porto Alegre, Porto Alegre, Brazil; Centre Antoine Lacassagne, Université Cô te d’Azur, Nice, France; Adelaide and Meath Hospital, University College Dublin, Dublin, Ireland; Eberhard Karls University of Tü bingen, Tü bingen, G; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.LBA4501-LBA4501)
-
354
- Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
- Westin, Jason; Oluwole, Olalekan O.; Kersten, Marie José ; Miklos, David Bernard; Perales, Miguel-Angel; Ghobadi, Armin; Rapoport, Aaron; Sureda, Anna; Jacobson, Caron Alyce; Farooq, Umar; van Meerten, Tom; Ulrickson, Matthew L.; Elsawy, Mahmoud; Leslie, Lori A.; Chaganti, Sridhar; Dickinson, Michael; Yang, Yin; Schupp, Marco Andreas; To, Christina Ann; Locke, Frederick L.; University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt University Cancer Center, Nashville, TN; Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; Stanford University School of Medicine, Stanford, CA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain; Dana-Farber Cancer Institute, Boston, MA; University of Iowa, Iowa City, IA; University Medical Center Groningen, Groningen, Netherlands; Banner MD Anderson Cancer Center, Gilbert, AZ; Division of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University and QEII Health Sciences Center, Halifax, NS, Canada; John Theurer Cancer Center, Hackensack, NJ; Centre for Clinical Haematology, University Hospitals Birmingham NHS Tr; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.LBA107-LBA107)
-
355
- A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).
- Veeraraghavan, Jamunarani; Gutierrez, Carolina; De Angelis, Carmine; Wang, Tao; Pascual, Tomá s; Weigelt, Britta; Galvan, Patricia; Rexer, Brent Neil; Forero-Torres, Andres; Wolff, Antonio C.; Nanda, Rita; Storniolo, Anna Maria; Krop, Ian E.; Goetz, Matthew P.; Reis-Filho, Jorge S.; Hilsenbeck, Susan G.; Prat, Aleix; Osborne, C. Kent; Schiff, Rachel; Rimawi, Mothaffar F.; Baylor College of Medicine, Houston, TX; ; Baylor College of Medicine, Houston, TX; ; Bayolor College of Medicine, Houston, TX; ; Baylor College of Medicine, Houston, TX; ; Department of Medical Oncology, Hospital Clí nic de Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI Breast Cancer Cooperative Group, Barcelona, Spain; ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; ; Department of Medical Oncology, Hospital Clí nic de Barcelona. Translational Genomics and Targeted Therapeutics in Solid Tumours Lab (IDIBAPS), Barcelona, Spain; ; Vanderbilt University Medical Center, Nashville, TN; ; University of Alabama at Birmingham, Birmingham, AL; ; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; ; The University of Chicago, Chicago, IL; ; Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indi; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.38, 2020, pp.1011-1011)
-
356
- GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014
- Heifetz, Alexander; Schertler, Gebhard F. X.; Seifert, Roland; Tate, Christopher G.; Sexton, Patrick M.; Gurevich, Vsevolod V.; Fourmy, Daniel; Cherezov, Vadim; Marshall, Fiona H.; Storer, R. Ian; Moraes, Isabel; Tikhonova, Irina G.; Tautermann, Christofer S.; Hunt, Peter; Ceska, Tom; Hodgson, Simon; Bodkin, Mike J.; Singh, Shweta; Law, Richard J.; Biggin, Philip C.; Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ UK; D-BIOL, ETH Zurich Paul Scherrer Institute, Laboratory of Biomolecular Research, LBR OFLC 109, CH-5232 Villigen PSI, Switzerland; Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany; MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, CB2 0QH UK; Drug Discovery Biology Monash Institute of Pharmaceutical Sciences 381 Royal Parade, Parkville, VIC 3052 Australia; Vanderbilt University Medical Center, 2200 Pierce Avenue, Preston Research Building, Nashville, TN 37232 USA; University of Toulouse, Bat L3, I2MC/INSERM U1048, Avenue Jean Poulhè s, 31432 Toulouse Cedex 4, France; Department of Chemistry, Bridge Institute, Los Angeles, CA USA; Heptares Therapeutics, Biopark, Welwyn Garden City, Hertfordshire AL7 3AX UK; Pfizer Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Cambridge, CB21 6; (Naunyn-Schmiedeberg's archives of pharmacology, v.388, 2015, pp.883-903)
-
357
- Design and quality control of large-scale two-sample Mendelian randomization studies
- Haycock, Philip C; Borges, Maria Carolina; Burrows, Kimberley; Lemaitre, Rozenn N; Harrison, Sean; Burgess, Stephen; Chang, Xuling; Westra, Jason; Khankari, Nikhil K; Tsilidis, Kostas K; Gaunt, Tom; Hemani, Gibran; Zheng, Jie; Truong, Therese; O’Mara, Tracy A; Spurdle, Amanda B; Law, Matthew H; Slager, Susan L; Birmann, Brenda M; Saberi Hosnijeh, Fatemeh; Mariosa, Daniela; Amos, Christopher I; Hung, Rayjean J; Zheng, Wei; Gunter, Marc J; Davey Smith, George; Relton, Caroline; Martin, Richard M; Department of Medicine, University of Washington , Seattle, WA, USA; MRC Biostatistics Unit, University of Cambridge , Cambridge, UK; Department of Mathematics, Statistics, and Computer Science, Dordt College, Sioux Center , IA, USA; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center , Nashville, TN, USA; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Team “Exposome, Heredity, Cancer and Health”, CESP , Villejuif, France; Department of Health Sciences Research, Mayo Clinic , Rochester, MN, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, MA, USA; Institute for Risk Assessment Sciences, Utrecht University , Utrecht, The Netherlands; Ge; (International journal of epidemiology, v.52, 2023, pp.1498-1521)
-
358
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
- Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Waddell, Tom; Gafanov, Rustem; Pouliot, Fré dé ric; Nosov, Dmitry; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Vynnychenko, Ihor O.; McDermott, Raymond S.; Azevedo, Sergio Jobim; Tamada, Satoshi; Kryzhanivska, Anna; Li, Chenxiang; Burgents, Joseph E.; Molife, L. Rhoda; Bedke, Jens; Powles, Thomas; Vanderbilt-Ingram Cancer Center, Nashville, TN; ; Fox Chase Cancer Center, Philadelphia, PA; ; Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro, Ukraine; ; The Christie NHS Foundation Trust, Manchester, United Kingdom; ; Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation; ; CHU of Qué bec and Laval University, Qué bec City, ON, Canada; ; Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation; ; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; ; Centre Hospitalier de l'Université de Montré al, Montré al, QC, Canada; ; Centre Antoine Lacassagne, Université Cô te d’Azur, Nice, France; ; Sumy State University, Sumy Regional Oncology Center, Sumy, Ukraine; ; Adelaide and Meath Hospital and University College Dublin, Dublin, Ireland; ; Hospital de Clí nicas de Porto Alegre, Porto Alegre, Brazil; ; Osaka City University Hospital, Osaka, Japa; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.4500-4500)
-
359
- Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).
- Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Perini, Rodolfo F.; Markensohn, Julia; Molife, L. Rhoda; Zhang, Yiwei; Nebozhyn, Michael; Loboda, Andrey; Vajdi, Amir; Powles, Thomas; Vanderbilt-Ingram Cancer Center, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; Dnipro State Medical University, Dnipro, Ukraine; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russian Federation; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; Central Clinical Hospital With Outpatient Clinic, Moscow, Russian Federation; CHU of Qué bec and Laval University, Quebec, QC, Canada; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russian Federation; Centre Hospitalier de l’Université de Montré al, Montreal, QC, Canada; Hospital de Clí nicas de Porto Alegre, Porto Alegre, Brazil; Centre Antoine Lacassagne, Université Cô te d’Azur, Nice, France; Adelaide and Meath Hospital, University College Dublin, Dublin, Ireland; Merck & Co., Inc., Rahway, NJ; Merck & Co., Inc., Rahway, NJ; MSD UK, London, United Kingdom; Merck & Co., Inc., Rah; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.42, 2024, pp.4505-4505)
-
360
- Clonal hematopoiesis associated with epigenetic aging and clinical outcomes
- Nachun, Daniel; Lu, Ake T.; Bick, Alexander G.; Natarajan, Pradeep; Weinstock, Joshua; Szeto, Mindy D.; Kathiresan, Sekar; Abecasis, Goncalo; Taylor, Kent D.; Guo, Xiuqing; Tracy, Russ; Durda, Peter; Liu, Yongmei; Johnson, Craig; Rich, Stephen S.; Van Den Berg, David; Laurie, Cecilia; Blackwell, Tom; Papanicolaou, George J.; Correa, Adolfo; Raffield, Laura M.; Johnson, Andrew D.; Murabito, Joanne; Manson, JoAnn E.; Desai, Pinkal; Kooperberg, Charles; Assimes, Themistocles L.; Levy, Daniel; Rotter, Jerome I.; Reiner, Alex P.; Whitsel, Eric A.; Wilson, James G.; Horvath, Steve; Jaiswal, Siddhartha; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA; Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Biostatistics, Univ; (Aging cell, v.20, 2021, pp.e13366)
QUICK MENU
